PTHS

SEC source: 0001753926-24-001131 · ownership.xml · derivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,165

Underlying: Common Stock · 64,498 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

SEC source: 0001753926-24-001137 · ownership.xml · derivative · entry 1

Simmons Chia-Lin · CIK 0001868194 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 90,000 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, the Reporting Person was granted stock options to purchase 90,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted stock options to purchase 90,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

SEC source: 0001753926-24-001135 · ownership.xml · derivative · entry 1

Lang Eric · CIK 0001984967 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,223

Underlying: Common Stock · 130,000 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, the Reporting Person was granted stock options to purchase 130,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted stock options to purchase 130,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

SEC source: 0001919246-26-000046 · wk-form4a_1775079918.xml · nonDerivative · entry 1

Davis Todd C · CIK 0001392029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,817

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,023

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001919246-26-000045 · wk-form4a_1775079878.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,450

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001753926-24-000376 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · Interim CEO, CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · Camden Capital LLC

Disclosed balance after: 25,001

Underlying: Common Stock · 2,778 shares

Expires 2033-01-10

F2 · price: On January 10, 2023, Camden Capital LLC was granted stock options to purchase 2,778 shares of common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.

F1 · ownership.nature: The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.

SEC source: 0001753926-24-000374 · ownership.xml · derivative · entry 2

Davis Todd C · CIK 0001392029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,167 shares

Expires 2024-02-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share.

SEC source: 0001753926-24-000374 · ownership.xml · nonDerivative · entry 1

Davis Todd C · CIK 0001392029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share.

F1 · price: Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share.

SEC source: 0001753926-24-000372 · ownership.xml · derivative · entry 4

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Balmoral Financial Group LLC

Disclosed balance after: 0

Underlying: Common Stock · 6,992 shares

Expires 2024-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F3 · price: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).

SEC source: 0001753926-24-000372 · ownership.xml · derivative · entry 3

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Balmoral Financial Group LLC

Disclosed balance after: 0

Underlying: Common Stock · 13,649 shares

Expires 2024-02-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F2 · price: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).

SEC source: 0001753926-24-000372 · ownership.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Balmoral Financial Group LLC

Disclosed balance after: 520,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F3 · shares: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F3 · price: Represents $33,136.00 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due March 1, 2024, which automatically converted into 6,992 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, including an additional 88 shares of common stock issued as consideration for this senior secured convertible promissory note.

F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).

SEC source: 0001753926-24-000372 · ownership.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Balmoral Financial Group LLC

Disclosed balance after: 513,727

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F2 · shares: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F2 · price: Represents $65,513.61 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 13,649 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.

F1 · ownership.nature: The securities are held by Balmoral Financial Group LLC ("Balmoral"). The Reporting Person serves as a manager of Balmoral, which also manages a retirement account for the Reporting Person, and, accordingly, the Reporting Person may also be deemed to beneficially own the shares of common stock held by Balmoral (or managed by Balmoral, in respect of the retirement account).

SEC source: 0001753926-24-000518 · ownership.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 545,721

F1 · security: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

F1 · kind: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

F1 · shares: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

F1 · price: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

F1 · balance_after: This Form 4/A is being filed to include the purchase of 16,667 shares of the Issuer's common stock (the "Common Stock") in the Issuer's initial public offering, in addition to the securities originally reported on the Form 4 filed by the reporting person on February 21, 2024.

SEC source: 0001753926-24-001139 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · Camden Capital LLC

Disclosed balance after: 25,001

Underlying: Common Stock · 2,778 shares

Expires 2033-01-10

F1 · price: On February 23, 2024, the Reporting Person filed a Form 4 which inadvertently reported that, Camden Capital LLC disposed of 2,778 shares of the Issuer's common stock. In fact, following the grant of stock options to Camden Capital LLC, it acquired 2,778 shares of the Issuer's common stock at an exercise price of $22.68 per share, which became exercisable upon the closing of Issuer's initial public offering.

F2 · ownership.nature: The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.